Scientists probe safety of common blood thinners for liver patients
NCT ID NCT04874428
Summary
This early-stage study aims to understand how two common oral blood thinners (rivaroxaban and apixaban) are processed by the body in people with compensated liver cirrhosis. It will enroll 24 participants who will receive a single dose of one medication, followed by multiple blood draws over 12 hours to measure drug levels and effects on blood clotting. The goal is to gather foundational safety and dosing data to inform larger future studies on using these drugs in this patient population.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Visceral Surgery and Medicine, University Hospital Inselspital, Berne
RECRUITINGBern, 3010, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.